Skip to content

Source filing unavailable

Q4 2017 · —
Revenue$4.04Mno prior Q4 2016 on file−76.9% vs Q3 2017
Net Income-$15.34Mno prior Q4 2016 on fileN/M vs Q3 2017
EPS Diluted-$33.51no prior Q4 2016 on fileN/M vs Q3 2017
Operating Cash Flowderived-$4,839,000—
Free Cash Flowderived-$5,496,000—
Margins · derived
Net margin-379.8%

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

no prior Q4 2016 on file

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR